$6.5
C4 Therapeutics is a biotechnology business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics employs 145 staff and has a trailing 12-month revenue of around $20 million.
Our top picks for where to buy C4 Therapeutics Inc stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- No-cost financial planning and automated investing
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
How to buy C4 Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CCCC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy C4 Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
C4 Therapeutics stock price (NASDAQ: CCCC)
Use our graph to track the performance of CCCC stocks over time.C4 Therapeutics shares at a glance
Latest market close | $6.44 |
---|---|
52-week range | $1.06 - $11.88 |
50-day moving average | $5.25 |
200-day moving average | $5.34 |
Wall St. target price | $18.86 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-2.37 |
Is it a good time to buy C4 Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
C4 Therapeutics price performance over time
Historical closes compared with the close of $6.44 from 2024-07-25
1 week (2024-07-19) | 6.80% |
---|---|
1 month (2024-06-27) | 39.39% |
3 months (2024-04-26) | 4.38% |
6 months (2024-01-26) | 17.73% |
1 year (2023-07-27) | 76.92% |
---|---|
2 years (2022-07-27) | -39.76% |
3 years (2021-07-27) | 41.16 |
5 years (2019-07-23) | N/A |
C4 Therapeutics financials
Revenue TTM | $20 million |
---|---|
Gross profit TTM | $-86,745,000 |
Return on assets TTM | -20.86% |
Return on equity TTM | -48.42% |
Profit margin | 0% |
Book value | $3.76 |
Market Capitalization | $414.9 million |
TTM: trailing 12 months
C4 Therapeutics share dividends
We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.
C4 Therapeutics share price volatility
Over the last 12 months, C4 Therapeutics's shares have ranged in value from as little as $1.06 up to $11.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while C4 Therapeutics's is 3.078. This would suggest that C4 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put C4 Therapeutics's beta into context you can compare it against those of similar companies.
- Regeneron Pharmaceuticals (REGN.US): 0.128
- Biogen (BIIB.US): -0.038
- Alector (ALEC.US): 0.724
C4 Therapeutics overview
C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. ; Biogen MA, Inc.
Frequently asked questions
nullWhat percentage of C4 Therapeutics is owned by insiders or institutions?
Currently 11.748% of C4 Therapeutics shares are held by insiders and 78.673% by institutions. How many people work for C4 Therapeutics?
Latest data suggests 145 work at C4 Therapeutics. When does the fiscal year end for C4 Therapeutics?
C4 Therapeutics's fiscal year ends in December. Where is C4 Therapeutics based?
C4 Therapeutics's address is: 490 Arsenal Way, Watertown, MA, United States, 02472 What is C4 Therapeutics's ISIN number?
C4 Therapeutics's international securities identification number is: US12529R1077
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
Ask a question